{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:45:59Z","timestamp":1782809159138,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.7759\/cureus.111786","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:12:00Z","timestamp":1782807120000},"source":"Crossref","is-referenced-by-count":0,"title":["Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Henna","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimul A","family":"Babli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlok H","family":"Khambholja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trimbakesh D","family":"Lingadahalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curie","family":"Villarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"UFN","family":"Rizwanullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sures","family":"Kumarsivarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Newton","family":"Rahming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashawna  S","family":"Drum Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren L","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opeyemi S","family":"Alamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Obesity and overweight. (2024). Accessed: May 30, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","unstructured":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019. a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020, 396:1223-49. 10.1016\/S0140-6736(20)30752-2","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher M","year":"2019","unstructured":"Bl\u00fcher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019, 15:288-98. 10.1038\/s41574-019-0176-8","journal-title":"Nat Rev Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12551","article-title":"Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation","volume":"18","author":"Bray GA","year":"2017","unstructured":"Bray GA, Kim KK, Wilding JP. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017, 18:715-23. 10.1111\/obr.12551","journal-title":"Obes Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran P","year":"2011","unstructured":"Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011, 365:1597-604. 10.1056\/NEJMoa1105816","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer X","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al.. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015, 373:11-22. 10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner RF","year":"2020","unstructured":"Kushner RF, Calanna S, Davies M, et al.. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020, 28:1050-61. 10.1002\/oby.22794","journal-title":"Obesity (Silver Spring)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden TA","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021, 325:1403-13. 10.1001\/jama.2021.1831","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey WT","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022, 28:2083-91. 10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker DJ","year":"2022","unstructured":"Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022, 57:101351. 10.1016\/j.molmet.2021.101351","journal-title":"Mol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller TD","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022, 21:201-23. 10.1038\/s41573-021-00337-8","journal-title":"Nat Rev Drug Discov"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)","volume":"402","author":"Garvey WT","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023, 402:613-26. 10.1016\/S0140-6736(23)01200-X","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity in an east","volume":"10","author":"Kadowaki T","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, et al.. Semaglutide once a week in adults with overweight or obesity in an east. Lancet Diabetes Endocrinol. 2022, 10:193-206. 10.1016\/S2213-8587(22)00008-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino D","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al.. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021, 325:1414-25. 10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding JP","year":"2022","unstructured":"Wilding JP, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022, 24:1553-64. 10.1111\/dom.14725","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren JR","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SB, et al.. Healthy weight loss maintenance with exercise, liraglutide, or both combined\r\n. N Engl J Med. 2021, 384:1719-30. 10.1056\/NEJMoa2028198","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.419","article-title":"Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare\u00ae patient support program","volume":"6","author":"Wharton S","year":"2020","unstructured":"Wharton S, Haase CL, Kamran E, et al.. Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare\u00ae patient support program. Obes Sci Pract. 2020, 6:382-9. 10.1002\/osp4.419","journal-title":"Obes Sci Pract"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn W","year":"2022","unstructured":"Ghusn W, De la Rosa A, Sacoto D, et al.. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022, 5:e2231982. 10.1001\/jamanetworkopen.2022.31982","journal-title":"JAMA Netw Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2023.07.006","article-title":"Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus","volume":"17","author":"Lee J","year":"2023","unstructured":"Lee J, Kim R, Kim MH, et al.. Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus. Prim Care Diabetes. 2023, 17:460-5. 10.1016\/j.pcd.2023.07.006","journal-title":"Prim Care Diabetes"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/lifemeta\/loaf024","article-title":"Weight loss maintenance after tirzepatide cessation in people with overweight\/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial","volume":"4","author":"Chen C","year":"2025","unstructured":"Chen C, Ying Z, Tang Q, et al.. Weight loss maintenance after tirzepatide cessation in people with overweight\/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial. Life Metab. 2025, 4:loaf024. 10.1093\/lifemeta\/loaf024","journal-title":"Life Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14142","article-title":"2024 clinical practice guidelines for the diagnosis and pharmacologic treatment of overweight and obesity by the Korean Society for the Study of Obesity","volume":"15","author":"Bae JY","year":"2024","unstructured":"Bae JY, Hee HJ, Jun E, Young KS, Song SJ, Park CY, Hyuktae K. 2024 clinical practice guidelines for the diagnosis and pharmacologic treatment of overweight and obesity by the Korean Society for the Study of Obesity. J Diabetes Investig. 2024, 15:429-36. 10.1111\/jdi.14142","journal-title":"J Diabetes Investig"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo CM","year":"2023","unstructured":"Perdomo CM, Cohen RV, Sumithran P, Cl\u00e9ment K, Fr\u00fchbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023, 401:1116-30. 10.1016\/S0140-6736(22)02403-5","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.6112","article-title":"Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial","volume":"186","author":"Horn DB","year":"2026","unstructured":"Horn DB, Linetzky B, Davies MJ, et al.. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial. JAMA Intern Med. 2026, 186:157-67. 10.1001\/jamainternmed.2025.6112","journal-title":"JAMA Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2196\/81912","article-title":"Semaglutide and tirzepatide in a remote weight management program: 12-month retrospective observational study","volume":"9","author":"Richards R","year":"2025","unstructured":"Richards R, Lunt W, Whitman M, Spaltro G, Hall R. Semaglutide and tirzepatide in a remote weight management program: 12-month retrospective observational study. JMIR Form Res. 2025, 9:e81912. 10.2196\/81912","journal-title":"JMIR Form Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen SB","year":"2024","unstructured":"Jensen SB, Blond MB, Sandsdal RM, et al.. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024, 69:102475. 10.1016\/j.eclinm.2024.102475","journal-title":"EClinicalMedicine"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/obendo\/wjaf011","article-title":"Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance","volume":"1","author":"Brufani C","year":"2025","unstructured":"Brufani C, Morviducci L. Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance. Obes Endocrinol. 2025, 1:wjaf011. 10.1093\/obendo\/wjaf011","journal-title":"Obes Endocrinol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2025.100788","article-title":"Real-world weight change pattern after glucagon-like peptide-1 receptor agonist discontinuation: a 1-year observational study","volume":"58","author":"Abdel-Bary M","year":"2025","unstructured":"Abdel-Bary M, Brody A, Schmitt J, Prieto K, Wetzel A, Juo YY. Real-world weight change pattern after glucagon-like peptide-1 receptor agonist discontinuation: a 1-year observational study. Obes Med. 2025, 58:100658. 10.1016\/j.obmed.2025.100788","journal-title":"Obes Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70660","article-title":"Obesity treatments and weight changes in clinical practice after discontinuation of semaglutide or tirzepatide","volume":"28","author":"Gasoyan H","year":"2026","unstructured":"Gasoyan H, Schulte R, Boyer CB, et al.. Obesity treatments and weight changes in clinical practice after discontinuation of semaglutide or tirzepatide. Diabetes Obes Metab. 2026, 28:4795-805. 10.1111\/dom.70660","journal-title":"Diabetes Obes Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1366940","article-title":"The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study","volume":"15","author":"Jensterle M","year":"2024","unstructured":"Jensterle M, Ferjan S, Janez A. The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study. Front Endocrinol (Lausanne). 2024, 15:1366940. 10.3389\/fendo.2024.1366940","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay I","year":"2023","unstructured":"Lingvay I, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023, 31:111-22. 10.1002\/oby.23621","journal-title":"Obesity (Silver Spring)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst JJ","year":"2020","unstructured":"Holst JJ, Rosenkilde MM. GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists. J Clin Endocrinol Metab. 2020, 105:e2710-6. 10.1210\/clinem\/dgaa327","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref38","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2013). Accessed. May 30, 2026: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986, 7:177-88. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref41","unstructured":"R Core Team. R: a language and environment for statistical computing. (2024). Accessed: May 30, 2026: https:\/\/www.R-project.org\/."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer W","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010, 36:1-48. 10.18637\/jss.v036.i03","journal-title":"J Stat Softw"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503146-post-cessation-weight-regain-after-weight-management-medications-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:12:09Z","timestamp":1782807129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503146-post-cessation-weight-regain-after-weight-management-medications-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.111786","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}